We are live on ! Find out more
SLNO

Soleno Therapeutics
SLNO

Delisted

SLNO was delisted on the 15th of May, 2026.

Back to rankings

0 hedge funds and large institutions have $0 invested in Soleno Therapeutics in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 220 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 225 → 0 (-225)

100% less funds holding in top 10

Funds holding in top 10: 5 → 0 (-5)

100% less capital invested

Capital invested by funds: $2.08B → $0 (-$2.08B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 220

120.6% less ownership

Funds ownership: 120.6% → 0% (-121%)

Holders
–
Holders Change
-225
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
220
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$194M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$148M
3
BlackRock
BlackRock
New York
-$125M
4
State Street
State Street
Massachusetts
-$89.8M
5
ACA
Avoro Capital Advisors
New York
-$77M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
101
Two Sigma Investments
New York
– -$1.61M -48,092 Closed
YIH
102
Y-Intercept (HK)
Hong Kong
– -$1.6M -47,731 Closed
ACM
103
ADAR1 Capital Management
Texas
– -$1.57M -46,830 Closed
RL
104
Ruffer LLP
United Kingdom
– -$1.57M -46,673 Closed
Invesco
105
Invesco
Georgia
– -$1.5M -44,814 Closed
AllianceBernstein
106
AllianceBernstein
Tennessee
– -$2M -43,090 Closed
BPC
107
Banque Pictet & Cie
Switzerland
– -$1.3M -38,730 Closed
PA
108
Profund Advisors
Maryland
– -$1.19M -35,607 Closed
Legal & General Group
109
Legal & General Group
United Kingdom
– -$1.18M -35,144 Closed
Los Angeles Capital Management
110
Los Angeles Capital Management
California
– -$1.12M -33,372 Closed
Lazard Asset Management
111
Lazard Asset Management
New York
– -$1.09M -32,664 Closed
D.E. Shaw & Co
112
D.E. Shaw & Co
New York
– -$1.01M -30,247 Closed
CF
113
Cantor Fitzgerald
New York
– -$1M -30,000 Closed
Vanguard Asset Management
114
Vanguard Asset Management
– -$1M -29,905 Closed
FMI
115
F/M Investments
District of Columbia
– -$983K -29,351 Closed
Mirae Asset Global ETFs Holdings
116
Mirae Asset Global ETFs Holdings
Hong Kong
– -$963K -29,288 Closed
FAM
117
Fred Alger Management
New York
– -$945K -28,215 Closed
MIM
118
MetLife Investment Management
New Jersey
– -$921K -27,501 Closed
Capital Fund Management (CFM)
119
Capital Fund Management (CFM)
France
– -$888K -26,511 Closed
TC
120
TwinBeech Capital
New York
– -$877K -26,200 Closed
EAM
121
Erste Asset Management
Austria
– -$779K -25,600 Closed
AIMCA
122
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
– -$837K -25,000 Closed
GC
123
Guggenheim Capital
Illinois
– -$814K -24,326 Closed
ECM
124
ExodusPoint Capital Management
New York
– -$778K -23,240 Closed
WAM
125
Weiss Asset Management
Massachusetts
– -$770K -23,000 Closed
3 4
5
6 7

SLNO Hedge Fund Activity: Q2 2026 in Review

0 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2026, worth a combined $0 — down 100% from $2.08B a quarter earlier.

Sellers outnumbered buyers: 220 funds closed out of SLNO and 0 opened new positions — a net loss of 220 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Fidelity Investments, exiting entirely with an estimated $194M sold.

  • 0 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2026, down from 225 in Q1 2026.
  • Funds reported $0 of Soleno Therapeutics stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Soleno Therapeutics positions in Q2 2026 and 220 closed out, a net change of -220 holders.
  • The largest Soleno Therapeutics seller in Q2 2026 was Fidelity Investments, an estimated $194M sold.

Based on aggregated 13F filings for Q2 2026.